IN THE SPECIFICATION:

Please replace paragraph [0021] with the following:

[0021] The target-binding site of a disease-targeting antibody arm is capable of binding to a complementary binding moiety on the target cells, tissues, pathogens or on a molecule produced by, or associated with, the target cell tissue or pathogen. In a preferred aspect of the present invention, the pathogen is selected from the group consisting of a virus, a fungus, a parasite and a bacterium. The complementary binding moieties that are contemplated in one aspect of the present invention include, but are not limited to tumor-associated antigens (TAAs), wherein said antigens are selected from the group consisting of AFP (alpha fetal protein), HCG (human chorionic gonadotropin), EGP-l, EGP-2, CD37, CD74, colon-specific antigen-p (CSAp), carcinoembryonic antigen (CEA), CD 19, CD20, CD21, CD22, CD23, CD30, CD74, CD80, HLA-DR, la, MUC 1, MUC 2, MUC 3, MUC 4, EGFR, HER 2/neu, PAM-4, TAG-72, EGP-1, EGP-2, A3, KS-1, Le(y), 5100, PSMA, PSA, tenascin, folate receptor, VEGFR, necrosis antigens, IL-2, T101 and MACE. Specific targeting antibodies include, but are not limited to: MN-14 (anti-carcinoembryonic antigen), Mu-9 (anti-colon specific antigen-P), LL2 (anti-CD22), LL1 (anti-CD74), hA20 (anti-CD20) RS7 (anti-epithelial glycoprotein). Such antibodies encompass chimeric, humanized and human antibodies containing the same CDRs as their corresponding murine antibodies. *See* U.S. Patent Nos. 5,874,540; 5,789,554 and 6,187,287. *See* also pending U.S. Patent Applications 10/116,116; 09/337,756, now U.S. Patent No. 7,074,405; 60/360,259; and 60/356,132.

Please replace paragraph [0030] with the following:

[0030] Many more such compositions can be envisaged as useful within the context of the current invention. *See* for example published U.S. application 20020006379, now U.S. Patent 6,962,702 and ~~pending~~ U.S. Application Serial No. 09/337,756, now U.S. Patent 7,074,405.